BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11132240)

  • 1. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.
    Woodland C; Ito S; Granvil CP; Wainer IW; Klein J; Koren G
    Life Sci; 2000 Nov; 68(1):109-17. PubMed ID: 11132240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tubule cell model for ifosfamide nephrotoxicity.
    Aleksa K; Halachmi N; Ito S; Koren G
    Can J Physiol Pharmacol; 2005 Jun; 83(6):499-508. PubMed ID: 16049550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal ontogeny of ifosfamide nephrotoxicity.
    Aleksa K; Halachmi N; Ito S; Koren G
    J Lab Clin Med; 2004 Dec; 144(6):285-93. PubMed ID: 15614250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity.
    Aleksa K; Matsell D; Krausz K; Gelboin H; Ito S; Koren G
    Pediatr Nephrol; 2005 Jul; 20(7):872-85. PubMed ID: 15875221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal clearance of ifosfamide.
    Springate J; Zamlauski-Tucker MJ; Lu H; Chan KK
    Drug Metab Dispos; 1997 Sep; 25(9):1081-2. PubMed ID: 9311624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.
    Springate J; Chan K; Lu H; Davies S; Taub M
    In Vitro Cell Dev Biol Anim; 1999 Jun; 35(6):314-7. PubMed ID: 10476917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo.
    Springate JE
    J Appl Toxicol; 1997; 17(1):75-9. PubMed ID: 9048231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity.
    Storme T; Deroussent A; Mercier L; Prost E; Re M; Munier F; Martens T; Bourget P; Vassal G; Royer J; Paci A
    J Pharmacol Exp Ther; 2009 Feb; 328(2):598-609. PubMed ID: 19017849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
    Zaki EL; Springate JE; Taub M
    Toxicol In Vitro; 2003 Aug; 17(4):397-402. PubMed ID: 12849722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels.
    Aleksa K; Ito S; Koren G
    J Lab Clin Med; 2004 Mar; 143(3):159-62. PubMed ID: 15007305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantioselective metabolism of ifosfamide by the kidney.
    Aleksa K; Ito S; Koren G
    Chirality; 2006 Jun; 18(6):398-405. PubMed ID: 16575879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.
    Choucha-Snouber L; Aninat C; Grsicom L; Madalinski G; Brochot C; Poleni PE; Razan F; Guillouzo CG; Legallais C; Corlu A; Leclerc E
    Biotechnol Bioeng; 2013 Feb; 110(2):597-608. PubMed ID: 22887128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo.
    Brain EG; Yu LJ; Gustafsson K; Drewes P; Waxman DJ
    Br J Cancer; 1998 Jun; 77(11):1768-76. PubMed ID: 9667645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide clinical pharmacokinetics.
    Wagner T
    Clin Pharmacokinet; 1994 Jun; 26(6):439-56. PubMed ID: 8070218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, mesna, and nephrotoxicity in children.
    Skinner R; Sharkey IM; Pearson AD; Craft AW
    J Clin Oncol; 1993 Jan; 11(1):173-90. PubMed ID: 8418231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide toxicity in cultured proximal renal tubule cells.
    Springate J; Taub M
    Pediatr Nephrol; 2007 Mar; 22(3):358-65. PubMed ID: 17072651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
    McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
    Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
    Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.